Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docetaxel + carboplatin + rucaparib
- Development stage
- Unknown
- Lead developer
- Clovis Oncology
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
The PLATI-PARP regimen is a sequential therapeutic strategy developed by the University of Washington and Fred Hutchinson Cancer Center for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in patients with homologous recombination repair (HRR) gene deficiencies. The regimen consists of an induction phase of chemotherapy using docetaxel and carboplatin, followed by a maintenance phase with the PARP inhibitor rucaparib. Docetaxel acts by stabilizing microtubules to inhibit cell division, while carboplatin creates DNA cross-links that cause structural damage. Rucaparib subsequently targets poly (ADP-ribose) polymerase (PARP) enzymes, preventing the repair of single-strand DNA breaks. In cells with existing HRR defects, this combination leads to the accumulation of double-strand breaks and selective tumor cell death through synthetic lethality.
- Other names
- b-University of Washington-prostate cancer (metastatic castration-resistant)induction docetaxel and carboplatin followed by maintenance rucaparib
02
Targets
PARP3 (Poly(adp-ribose) polymerase 3)DNATUBB (Tubulin (alpha and beta subunits))PARP2 (Poly (adp-ribose) polymerase 2)
Beyond the preview
Go deeper on docetaxel + carboplatin + rucaparib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docetaxel + carboplatin + rucaparib.